RESUMEN
The production of high-quality purified virus particles in high quantities for vaccine preparation requires a scalable purification procedure in the downstream step. A purification scheme based on combined strong anion-exchange and size exclusion chromatography (2D-AEC-SEC) was developed for the production of non-structural protein-free foot and mouth disease vaccine, and the whole procedure was accomplished with 77.9% virus yield. Additionally, a mathematical modeling and a simulation approach based on a plate model of chromatography were developed and matched with the experimental chromatography data to improve prediction of retention behavior and save time in the development of the downstream scale-up method. The purified pooled virus fraction obtained from the final polishing step had a purity higher than 85% based on analytical size exclusion analysis. Moreover, more than 90.1% of residual DNA (rDNA) was removed from the purified vaccine. The analysis of purified virus particles by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), dynamic light scattering (DLS), high performance size exclusion chromatography (HP-SEC), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and transmission electron microscopy (TEM) provided clear evidence of purity and demonstrated that the final product is structurally spherical, intact particles qualified for formulation as a vaccine product.
Asunto(s)
Cromatografía en Gel/métodos , Cromatografía por Intercambio Iónico/métodos , Modelos Teóricos , Vacunas Virales/análisis , Animales , Línea Celular , Cricetinae , Dispersión Dinámica de Luz , Electroforesis en Gel de Poliacrilamida , Fiebre Aftosa/prevención & control , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Vacunas Virales/aislamiento & purificación , Inactivación de VirusRESUMEN
Fowlpox virus (FWPV), which is the type member of the genus Avipoxvirus, subfamily Chordopoxvirinae, family Poxviridae, can lead to significant losses to the poultry industry. Although a large number of fowlpox virus genomes have been sequenced and characterised globally, there are no sequences available at the genomic level from Australian isolates. Here, we present the first complete genome sequence of a fowlpox virus vaccine strain (FWPV-S) containing an integrated near-full-length reticuloendotheliosis virus (REV) provirus. The genome of FWPV-S showed the highest sequence similarity to a fowlpox virus from the USA (97.74% identity). The FWPV-S genome contained 16 predicted unique genes, while a further two genes were fragmented compared to previously reported FWPV genome sequences. Subsequent phylogenetic analysis showed that FWPV-S was most closely related to other fowlpox viruses. This is the first reported genome sequence of FWPV from Australia.
Asunto(s)
Virus de la Viruela de las Aves de Corral/genética , Provirus/genética , Virus de la Reticuloendoteliosis/genética , Vacunas Virales/genética , Animales , Australia , Secuencia de Bases , Células Cultivadas , Embrión de Pollo , ADN Viral/genética , Virus de la Viruela de las Aves de Corral/clasificación , Virus de la Viruela de las Aves de Corral/aislamiento & purificación , Genes Virales , Genoma Viral/genética , Sistemas de Lectura Abierta , Filogenia , Vacunas Virales/clasificación , Vacunas Virales/aislamiento & purificación , Integración ViralRESUMEN
The increasing medical interest in viral nanoplexes, such as viruses or virus-like particles used for vaccines, gene therapy products, or oncolytic agents, raises the need for fast and efficient production processes. In general, these processes comprise upstream and downstream processing. For the upstream process, efficiency is mainly characterized by robustly achieving high titer yields, while reducing process times and costs with regard to the cell culture medium, the host cell selection, and the applied process conditions. The downstream part, on the other hand, should effectively remove process-related contaminants, such as host cells/cell debris as well as host cell DNA and proteins, while maintaining product stability and reducing product losses. This chapter outlines a combination of process steps to successfully produce virus particles in the controlled environment of a stirred tank bioreactor, combined with a platform-based purification approach using filtration-based clarification and steric exclusion chromatography. Additionally, suggestions for off-line analytics in terms of virus characterization and quantification as well as for contaminant estimation are provided.
Asunto(s)
Reactores Biológicos , Nanocompuestos , Vacunología/métodos , Vacunas Virales/biosíntesis , Vacunas Virales/aislamiento & purificación , Animales , Técnicas de Cultivo de Célula , Humanos , Vacunas de Partículas Similares a Virus/biosíntesis , Vacunas de Partículas Similares a Virus/inmunología , Vacunas de Partículas Similares a Virus/aislamiento & purificación , Vacunas Virales/inmunología , Virión/aislamiento & purificaciónRESUMEN
BACKGROUND: The purification of expressed proteins is the most critical part of subunit-- vaccine production. Protein-purification methods such as affinity chromatography and ion exchange still have the shortcomings of being time consuming and complicated. With the rapid development of computational molecular-simulation technology, structure-based peptide-ligand design has become feasible. Objection: We aimed to apply molecular docking for a peptide ligand designed for classical swine fever virus (CSFV) E2 purification. METHODS: Computational-derived peptides were synthesized, and the in vitro binding interaction with E2 was investigated. The effects of purification on E2 were also evaluated. RESULTS: The best peptide recognizing E2 was P6, which had a sequence of KKFYWRYWEH. Based on kinetic surface plasmon resonance (SPR) analysis, the apparent affinity constant of P6 was found to be 148 nM. Importantly, P6 showed suitable binding affinity and specificity for E2 purification from transgenic rice seeds. Evaluation of immune antibodies in mice showed that the antibody- blocking rate on day 42 after inoculation reached 86.18% and 90.68%. CONCLUSION: The computational-designed peptide in this study has high sensitivity and selectivity and is thus useful for the purification of CSFV E2. The novel method of design provided a broad platform and powerful tool for protein-peptide screening, as well as new insights into CSFV vaccine design.
Asunto(s)
Virus de la Fiebre Porcina Clásica , Simulación del Acoplamiento Molecular , Proteínas del Envoltorio Viral , Vacunas Virales , Animales , Anticuerpos Antivirales/inmunología , Virus de la Fiebre Porcina Clásica/química , Virus de la Fiebre Porcina Clásica/genética , Virus de la Fiebre Porcina Clásica/inmunología , Porcinos , Vacunación , Vacunas de Subunidad/química , Vacunas de Subunidad/inmunología , Proteínas del Envoltorio Viral/química , Proteínas del Envoltorio Viral/genética , Proteínas del Envoltorio Viral/inmunología , Proteínas del Envoltorio Viral/aislamiento & purificación , Vacunas Virales/química , Vacunas Virales/genética , Vacunas Virales/inmunología , Vacunas Virales/aislamiento & purificaciónRESUMEN
There is growing interest in the development of new vaccines based on live-attenuated viruses (LAVs) and virus-like particles. The large size of these vaccines, typically 100-400 nm, significantly complicates the use of sterile filtration. The objectives of this study are to examine the performance of several commercial sterile filters for filtration of a cytomegalovirus vaccine candidate (referred to as the LAV) and to develop and evaluate the use of a model nanoparticle suspension to perform a more quantitative assessment. Data obtained with a mixture of 200- and 300-nm fluorescent particles provided yield and pressure profiles that captured the behavior of the viral vaccine. This included the excellent performance of the Sartorius Sartobran P filter, which provided greater than 80% yield of both the vaccine and model particles even though the average particle size was more than 250 nm. The particle yield for the Sartobran P was independent of filtrate flux above 200 L/m2 /h, but increased with increasing particle concentration, varying from less than 10% at concentrations around 107 particles/ml to more than 80% at concentrations above 1010 particles/ml due to saturation of particle capture/binding sites within the filter. These results provide important insights into the factors controlling transmission and fouling during sterile filtration of large vaccine products.
Asunto(s)
Nanopartículas/química , Vacunas Virales , Virus , Tamaño de la Partícula , Ultrafiltración , Vacunas Atenuadas/química , Vacunas Atenuadas/aislamiento & purificación , Vacunas Virales/química , Vacunas Virales/aislamiento & purificación , Virus/química , Virus/aislamiento & purificaciónRESUMEN
Although polyethylene glycol (PEG) application is the most widely used method in removing nonstructural proteins (NSPs) for foot-and-mouth disease (FMD) vaccine production, some NSPs remaining in the antigen could elicit antibodies against these proteins after repeated vaccinations in livestock. Therefore, the purpose of this study was to purify the FMD virus (FMDV) via affinity chromatography using a heparin ligand to remove most proteins, including NSPs. Chromatography showed an intact virus (146S) particle recovery of 70% or more for three different strains of serotype O FMDV (two locally isolated strains and one genetically modified strain). The experimental vaccine made with antigens eluted via heparin affinity chromatography elicited virus-neutralizing antibodies against homologous viruses but did not induce antibodies against NSPs even after five immunizations in goats; this indicated that the NSPs were effectively removed from the vaccine antigen. This method can then be used to produce a higher-quality vaccine compared with PEG application in terms of the purity of the FMD vaccine. Therefore, this result would be an important groundwork for advanced FMD vaccine manufacturing in the near future.
Asunto(s)
Antígenos Virales/inmunología , Cromatografía de Afinidad , Virus de la Fiebre Aftosa/inmunología , Fiebre Aftosa/inmunología , Proteínas no Estructurales Virales/inmunología , Vacunas Virales/inmunología , Vacunas Virales/aislamiento & purificación , Animales , Anticuerpos Antivirales/inmunología , Línea Celular , Fiebre Aftosa/prevención & control , Virus de la Fiebre Aftosa/clasificación , Cabras , Heparina , Inmunización , Inmunogenicidad Vacunal , Serogrupo , Proteínas no Estructurales Virales/aislamiento & purificaciónRESUMEN
PURPOSE: The vaccine design has shifted from attenuated or inactivated whole pathogen vaccines to more pure and defined subunit vaccines. The purification of antigen proteins, especially the precise display of antigen regions, has become a key step affecting the effectiveness of subunit vaccines. MATERIALS AND METHODS: This work presents the application of molecular docking for a peptide ligand designed for PCV2 Cap purification and assembly in one step. Based on the PCV2 Cap protein affinity peptide (L11-DYWWQSWE), the amino terminal of PCV2 Cap was covalently coupled with the polylactic acid-glycolic acid copolymer (PLGA) carboxyl terminal through the EDC/NHS method. RESULTS: The PLGA had an average diameter of 106 nm. The average diameter increased to 122 nm after the PCV2 Cap protein conjugation, and the Zeta potential shifted from -13.7 mV to -9.6 mV, indicating that the PCV2 Cap protein stably binds to the PLGA. Compared with the free PCV2 Cap protein group, the neutralizing antibody titer was significantly increased on the 14th day after the PLGA-Cap immunization (P < 0.05). The neutralizing antibody level was extremely significant on the 28th day (P < 0.001). The CCK-8 analysis showed that PLGA-Cap had an obvious cytotoxic effect on RAW264.7 cells at the PLGA nanoparticle concentration up to 200 µg/mL but had no obvious cytotoxic effect on DC2.4 cells. Compared with the Cap protein group, the antigen-presenting cells had a stronger antigen uptake capacity and a higher fluorescence in the PLGA-Cap group. The immune effect showed that the level of the neutralizing antibody produced by this structure is much better than that of purified protein and helps improve the immune system response. CONCLUSION: This technology provides a potential new perspective for the rapid enrichment of the antigen protein with the affinity peptide ligand.
Asunto(s)
Proteínas de la Cápside/inmunología , Circovirus/inmunología , Nanopartículas/química , Péptidos/inmunología , Vacunas Virales/inmunología , Vacunas Virales/aislamiento & purificación , Animales , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Células Presentadoras de Antígenos/metabolismo , Sitios de Unión , Línea Celular , Infecciones por Circoviridae/inmunología , Citocinas/biosíntesis , Inflamación/patología , Ligandos , Ratones , Simulación del Acoplamiento Molecular , Nanopartículas/ultraestructura , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/químicaAsunto(s)
Betacoronavirus , Infecciones por Coronavirus/prevención & control , Pandemias/prevención & control , Neumonía Viral/prevención & control , Vacunas Virales , Animales , Betacoronavirus/genética , Betacoronavirus/inmunología , Biotecnología , COVID-19 , Vacunas contra la COVID-19 , Ensayos Clínicos Fase III como Asunto , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/virología , Modelos Animales de Enfermedad , Desarrollo de Medicamentos/métodos , Desarrollo de Medicamentos/tendencias , Vectores Genéticos , Salud Global , Interacciones Microbiota-Huesped/inmunología , Humanos , Inmunidad Celular , Inmunidad Colectiva , Inmunidad Humoral , Neumonía Viral/inmunología , Neumonía Viral/virología , SARS-CoV-2 , Seguridad , Glicoproteína de la Espiga del Coronavirus/genética , Glicoproteína de la Espiga del Coronavirus/inmunología , Investigación Biomédica Traslacional , Vacunas de ADN/genética , Vacunas de ADN/aislamiento & purificación , Vacunas Sintéticas/genética , Vacunas Sintéticas/aislamiento & purificación , Vacunas Virales/administración & dosificación , Vacunas Virales/aislamiento & purificación , Vacunas Virales/normasRESUMEN
The outbreak of Coronavirus disease of 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has posed a serious health threat. The increasing number of COVID-19 cases around the world is overwhelming hospitals and pushing the global death toll to over 746,000, which has pushed the sprint to find new treatment options. In this article, we reviewed the SARS-CoV-2 pathophysiology, transmission, and potential treatment strategies.
Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/fisiopatología , Infecciones por Coronavirus/terapia , Neumonía Viral/fisiopatología , Neumonía Viral/terapia , Antivirales/uso terapéutico , Betacoronavirus/genética , Betacoronavirus/patogenicidad , Betacoronavirus/fisiología , COVID-19 , Vacunas contra la COVID-19 , Ensayos Clínicos como Asunto , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Susceptibilidad a Enfermedades , Humanos , Modelos Biológicos , Pandemias , Neumonía Viral/epidemiología , SARS-CoV-2 , Investigación Biomédica Traslacional , Vacunas Virales/aislamiento & purificación , Vacunas Virales/farmacología , Tratamiento Farmacológico de COVID-19RESUMEN
Porcine circovirus type 2 (PCV2) is a major pathogen associated with swine diseases. It is the smallest single-stranded DNA virus, and its genome contains four major open reading frames (ORFs). ORF2 encodes the major structural protein Cap, which can self-assemble into virus-like particles (VLPs) in vitro and contains the primary antigenic determinants. In this study, we developed a high-efficiency method for obtaining VLPs and optimized the purification conditions. In this method, we expressed the protein Cap with a 6× His tag using baculovirus-infected silkworm larvae as well as the E. coli BL21(DE3) prokaryotic expression system. The PCV2 Cap proteins produced by the silkworm larvae and E. coli BL21(DE3) were purified. Cap proteins purified from silkworm larvae self-assembled into VLPs in vitro, while the Cap proteins purified from bacteria were unable to self-assemble. Transmission electron microscopy confirmed the self-assembly of VLPs. The immunogenicity of the VLPs produced using the baculovirus system was demonstrated using an enzyme-linked immunosorbent assay (ELISA). Furthermore, the purification process was optimized. The results demonstrated that the expression system using baculovirus-infected silkworm larvae is a good choice for obtaining VLPs of PCV2 and has potential for the development of a low-cost and efficient vaccine.
Asunto(s)
Anticuerpos Antivirales/biosíntesis , Baculoviridae/genética , Bombyx/virología , Proteínas de la Cápside/inmunología , Circovirus/inmunología , Vacunas de Partículas Similares a Virus/biosíntesis , Vacunas Virales/biosíntesis , Animales , Antígenos Virales/química , Antígenos Virales/inmunología , Baculoviridae/inmunología , Proteínas de la Cápside/biosíntesis , Proteínas de la Cápside/genética , Infecciones por Circoviridae/inmunología , Infecciones por Circoviridae/prevención & control , Infecciones por Circoviridae/virología , Circovirus/genética , Epítopos/química , Epítopos/inmunología , Escherichia coli/genética , Escherichia coli/metabolismo , Femenino , Vectores Genéticos/química , Vectores Genéticos/metabolismo , Histidina/genética , Histidina/inmunología , Sueros Inmunes/química , Inmunogenicidad Vacunal , Larva/virología , Ratones , Oligopéptidos/genética , Oligopéptidos/inmunología , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Porcinos , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/prevención & control , Enfermedades de los Porcinos/virología , Vacunas de Partículas Similares a Virus/administración & dosificación , Vacunas de Partículas Similares a Virus/genética , Vacunas de Partículas Similares a Virus/aislamiento & purificación , Vacunas Virales/administración & dosificación , Vacunas Virales/genética , Vacunas Virales/aislamiento & purificaciónRESUMEN
The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.
Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/prevención & control , Pandemias/prevención & control , Neumonía Viral/inmunología , Neumonía Viral/prevención & control , Vacunas Virales/aislamiento & purificación , Animales , Antígenos Virales/química , Antígenos Virales/genética , Betacoronavirus/genética , Betacoronavirus/inmunología , COVID-19 , Vacunas contra la COVID-19 , Infecciones por Coronavirus/epidemiología , Interacciones Microbiota-Huesped/inmunología , Humanos , Inmunidad Celular , Inmunidad Humoral , Inmunidad Innata , Modelos Animales , Neumonía Viral/epidemiología , Primates , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/genética , Glicoproteína de la Espiga del Coronavirus/inmunología , Vacunas Virales/administración & dosificación , Vacunas Virales/inmunologíaRESUMEN
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently become a pandemic. As the sudden emergence and rapid spread of SARS-CoV-2 is endangering global health and the economy, the development of strategies to contain the virus's spread are urgently needed. At present, various diagnostic kits to test for SARS-CoV-2 are available for use to initiate appropriate treatment faster and to limit further spread of the virus. Several drugs have demonstrated in vitro activity against SARS-CoV-2 or potential clinical benefits. In addition, institutions and companies worldwide are working tirelessly to develop treatments and vaccines against COVID-19. However, no drug or vaccine has yet been specifically approved for COVID-19. Given the urgency of the outbreak, we focus here on recent advances in the diagnostics, treatment, and vaccine development for SARS-CoV-2 infection, helping to guide strategies to address the current COVID-19 pandemic.
Asunto(s)
Betacoronavirus , Técnicas de Laboratorio Clínico , Infecciones por Coronavirus , Pandemias , Neumonía Viral , Vacunas Virales , Antivirales/aislamiento & purificación , Antivirales/uso terapéutico , Betacoronavirus/genética , Betacoronavirus/inmunología , Betacoronavirus/aislamiento & purificación , COVID-19 , Prueba de COVID-19 , Vacunas contra la COVID-19 , Técnicas de Laboratorio Clínico/tendencias , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/terapia , Desarrollo de Medicamentos/tendencias , Humanos , Inmunización Pasiva/tendencias , Pandemias/prevención & control , Neumonía Viral/diagnóstico , Neumonía Viral/prevención & control , Neumonía Viral/terapia , SARS-CoV-2 , Nanomedicina Teranóstica/tendencias , Vacunas Virales/aislamiento & purificación , Vacunas Virales/farmacología , Tratamiento Farmacológico de COVID-19 , Sueroterapia para COVID-19RESUMEN
This review provides an update for the international research community on the cell modeling tools that could accelerate the understanding of SARS-CoV-2 infection mechanisms and could thus speed up the development of vaccines and therapeutic agents against COVID-19. Many bioengineering groups are actively developing frontier tools that are capable of providing realistic three-dimensional (3D) models for biological research, including cell culture scaffolds, microfluidic chambers for the culture of tissue equivalents and organoids, and implantable windows for intravital imaging. Here, we review the most innovative study models based on these bioengineering tools in the context of virology and vaccinology. To make it easier for scientists working on SARS-CoV-2 to identify and apply specific tools, we discuss how they could accelerate the discovery and preclinical development of antiviral drugs and vaccines, compared to conventional models.
Asunto(s)
Antivirales/aislamiento & purificación , Antivirales/farmacología , Betacoronavirus , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/prevención & control , Pandemias/prevención & control , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/prevención & control , Vacunas Virales/aislamiento & purificación , Vacunas Virales/farmacología , Betacoronavirus/química , Betacoronavirus/genética , Betacoronavirus/inmunología , Bioingeniería/métodos , Bioingeniería/tendencias , Reactores Biológicos , COVID-19 , Vacunas contra la COVID-19 , Técnicas de Cultivo de Célula , Simulación por Computador , Infecciones por Coronavirus/inmunología , Descubrimiento de Drogas/métodos , Descubrimiento de Drogas/tendencias , Evaluación de Medicamentos/métodos , Evaluación de Medicamentos/tendencias , Farmacorresistencia Viral , Interacciones Microbiota-Huesped/genética , Interacciones Microbiota-Huesped/inmunología , Humanos , Modelos Biológicos , Organoides/citología , Organoides/virología , Neumonía Viral/inmunología , SARS-CoV-2 , Nanomedicina TeranósticaRESUMEN
The COVID-19 pandemic is an emerging threat to global public health. While our current understanding of COVID-19 pathogenesis is limited, a better understanding will help us develop efficacious treatment and prevention strategies for COVID-19. One potential therapeutic target is angiotensin converting enzyme 2 (ACE2). ACE2 primarily catalyzes the conversion of angiotensin I (Ang I) to a nonapeptide angiotensin or the conversion of angiotensin II (Ang II) to angiotensin 1-7 (Ang 1-7) and has direct effects on cardiac function and multiple organs via counter-regulation of the renin-angiotensin system (RAS). Significant to COVID-19, ACE2 is postulated to serve as a major entry receptor for SARS-CoV-2 in human cells, as it does for SARS-CoV. Many infected individuals develop COVID-19 with fever, cough, and shortness of breath that can progress to pneumonia. Disease progression promotes the activation of immune cells, platelets, and coagulation pathways that can lead to multiple organ failure and death. ACE2 is expressed by epithelial cells of the lungs at high level, a major target of the disease, as seen in post-mortem lung tissue of patients who died with COVID-19, which reveals diffuse alveolar damage with cellular fibromyxoid exudates bilaterally. Comparatively, ACE2 is expressed at low level by vascular endothelial cells of the heart and kidney but may also be targeted by the virus in severe COVID-19 cases. Interestingly, SARS-CoV-2 infection downregulates ACE2 expression, which may also play a critical pathogenic role in COVID-19. Importantly, targeting ACE2/Ang 1-7 axis and blocking ACE2 interaction with the S protein of SARS-CoV-2 to curtail SARS-CoV-2 infection are becoming very attractive therapeutics potential for treatment and prevention of COVID-19. Here, we will discuss the following subtopics: 1) ACE2 as a receptor of SARS-CoV-2; 2) clinical and pathological features of COVID-19; 3) role of ACE2 in the infection and pathogenesis of SARS; 4) potential pathogenic role of ACE2 in COVID-19; 5) animal models for pathological studies and therapeutics; and 6) therapeutics development for COVID-19.
Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/metabolismo , Infecciones por Coronavirus/virología , Peptidil-Dipeptidasa A/metabolismo , Neumonía Viral/metabolismo , Neumonía Viral/virología , Receptores Virales/metabolismo , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Enzima Convertidora de Angiotensina 2 , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Animales , Anticuerpos Neutralizantes/uso terapéutico , Anticuerpos Antivirales/uso terapéutico , Antivirales/uso terapéutico , Betacoronavirus/química , Betacoronavirus/patogenicidad , Betacoronavirus/fisiología , COVID-19 , Vacunas contra la COVID-19 , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/terapia , Modelos Animales de Enfermedad , Interacciones Microbiota-Huesped/fisiología , Humanos , Ratones , Modelos Biológicos , Pandemias , Neumonía Viral/terapia , Sistema Renina-Angiotensina/fisiología , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/genética , Glicoproteína de la Espiga del Coronavirus/metabolismo , Nanomedicina Teranóstica , Vacunas Virales/aislamiento & purificación , Internalización del VirusRESUMEN
COVID-19 poses an extraordinary threat to global public health and an effective vaccine could provide a key means of overcoming this crisis. Human challenge studies involve the intentional infection of research participants and can accelerate or improve vaccine development by rapidly providing estimates of vaccine safety and efficacy. Human challenge studies of low virulence coronaviruses have been done in the past and human challenge studies with severe acute respiratory syndrome coronavirus 2 have been proposed. These studies of coronaviruses could provide considerable benefits to public health; for instance, by improving and accelerating vaccine development. However, human challenge studies of severe acute respiratory syndrome coronavirus 2 in particular might be controversial, in part, for ethical reasons. The ethical issues raised by such studies thus warrant early consideration involving, for example, broad consultation with the community. This Personal View provides preliminary analyses of relevant ethical considerations regarding human challenge studies of severe acute respiratory syndrome coronavirus 2, including the potential benefits to public health and to participants, the risks and uncertainty for participants, and the third-party risks (ie, to research staff and the wider community). We argue that these human challenge studies can reasonably be considered ethically acceptable insofar as such studies are accepted internationally and by the communities in which they are done, can realistically be expected to accelerate or improve vaccine development, have considerable potential to directly benefit participants, are designed to limit and minimise risks to participants, and are done with strict infection control measures to limit and reduce third-party risks.
Asunto(s)
Betacoronavirus/inmunología , Infecciones por Coronavirus/prevención & control , Desarrollo de Medicamentos/ética , Experimentación Humana/ética , Pandemias/prevención & control , Neumonía Viral/prevención & control , Vacunas Virales/inmunología , Vacunas Virales/aislamiento & purificación , Betacoronavirus/patogenicidad , COVID-19 , Desarrollo de Medicamentos/métodos , Humanos , SARS-CoV-2RESUMEN
African swine fever (ASF) is an infectious disease of domestic and wild pigs, caused by ASF virus (ASFV). In this study, a triplex real-time PCR assay was developed to detect and differentiate the gene-deleted and wild-type ASFV strains. Three pairs of primers and probes were designed to target the conserved region of B646L gene (p72), MGF_360-14L gene (located in the middle of MGF360-505R gene) and CD2v gene, respectively. Gene-deleted (with MGF360-505R and / or CD2v genes deletion) and wild-type ASFV strains were detected specifically and simultaneously by the assay developed without cross-reactions with other nucleic acids of PCV-2, CSFV, PRRSV, FMDV or SVA. The detection limits of the triplex rPCR were 7.9 copies, 9.7 copies, and 9.6 copies of standard plasmid DNA containing B646L gene, MGF_360-14L gene and CD2v gene, respectively. A total of 1215 field samples were tested in parallel by the triplex rPCR and real-time PCR recommended by OIE, and the B646L gene detection results were completely consistent between these two assays. The triplex rPCR assay was successfully developed to identify pigs infected with wild-type ASFV strains or immunized with the ASFV gene-deleted vaccine.
Asunto(s)
Virus de la Fiebre Porcina Africana/aislamiento & purificación , Fiebre Porcina Africana/diagnóstico , Técnicas de Diagnóstico Molecular/veterinaria , Reacción en Cadena de la Polimerasa Multiplex/veterinaria , Reacción en Cadena en Tiempo Real de la Polimerasa/veterinaria , Fiebre Porcina Africana/prevención & control , Virus de la Fiebre Porcina Africana/genética , Animales , ADN Viral/genética , Eliminación de Gen , Genes Virales/genética , Genoma Viral/genética , Sensibilidad y Especificidad , Sus scrofa , Porcinos , Vacunas Virales/genética , Vacunas Virales/aislamiento & purificaciónRESUMEN
A study was conducted to evaluate mucoadhesive property and immunomodulatory effect of phytogenic gums from Boswellia frereana, Boswellia carteri andCommiphora myrrha on intranasal Peste des petits ruminants (PPR) vaccination in goats and sheep in an ex-vivo and in-vivo situations. Plant gums were purified, dried and compressed into 500gm tablets. Modified shear stress measurement technique was used on freshly excised trachea and intestine tissues of goat to measure peak adhesion time. Forty eight animals (24 goats and 24 sheep) were divided into eight groups (of 3 goats and 3 sheep) and immunized intranasally with gum-vaccine combinations in two ratios (1:1, 1:2). Antibody against PPR virus was measured on day 14, 28, 42 and 56 post vaccination using H-based PPR bELISA. The peak adhesion time of the different gums was transient. PPR virus antibodies were detected in all immunized goats and sheep but not in unvaccinated control. The best percentage inhibition was recorded for Boswellia carteri-vaccine combination group at a ratio of 1:1. Administration of Boswellia carteri-PPR vaccine combination through intranasal or subcutaneous route, elicited similar antibody titre, implying that the intranasal route may be used as a non-invasive alternative delivery in PPR vaccination of small ruminants.
Asunto(s)
Anticuerpos Antivirales/inmunología , Boswellia/química , Boswellia/inmunología , Peste de los Pequeños Rumiantes/inmunología , Resinas de Plantas/administración & dosificación , Resinas de Plantas/farmacología , Vacunación , Vacunas Virales/inmunología , Adhesividad , Administración Intranasal , Animales , Anticuerpos Antivirales/administración & dosificación , Anticuerpos Antivirales/aislamiento & purificación , Mucosa Gástrica , Cabras , Peste de los Pequeños Rumiantes/terapia , Virus de la Peste de los Pequeños Rumiantes/inmunología , Resinas de Plantas/aislamiento & purificación , Ovinos , Vacunas Virales/administración & dosificación , Vacunas Virales/aislamiento & purificaciónRESUMEN
Infectious Bronchitis Virus (IBV) is a highly contagious virus of chicken, causing huge economic losses in the poultry industry. Many genotypes circulate in a given area, and optimal protection relies on vaccination with live attenuated vaccines of the same genotype. As these live vaccines are derived from field viruses and circulate, understanding the prevalence of different IBV genotypes in any area is complex. In a recent study, the genome comparison of an IBV QX vaccine and its progenitor field strain led to the identification of vaccine markers. Here we developed a simplex SYBRgreen RT-qPCR assay for differentiation between QX-like field and vaccine strains and a multiplex SYBRgreen RT-qPCR assay for IBV genotyping with melting curve analysis, as each virus produced distinct and reliable melting peaks. Both the simplex and the multiplex assays showed excellent efficiency, sensitivity and specificity representing a low cost diagnostic tool for IBV genotyping and vaccine differentiation.
Asunto(s)
Infecciones por Coronavirus/veterinaria , Virus de la Bronquitis Infecciosa/genética , Técnicas de Diagnóstico Molecular/métodos , Enfermedades de las Aves de Corral/diagnóstico , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Vacunas Virales/genética , Animales , Pollos , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/virología , Genotipo , Virus de la Bronquitis Infecciosa/aislamiento & purificación , Técnicas de Diagnóstico Molecular/veterinaria , Enfermedades de las Aves de Corral/virología , Reacción en Cadena en Tiempo Real de la Polimerasa/veterinaria , Sensibilidad y Especificidad , Vacunas Atenuadas/genética , Vacunas Atenuadas/aislamiento & purificación , Proteínas Virales/genética , Vacunas Virales/aislamiento & purificaciónRESUMEN
Chimeric virus-like particles (VLP) are known as promising tools in the development of safe and effective subunit vaccines. Recently, a technology platform to produce VLP based on the small surface protein (dS) of the duck hepatitis B virus was established. In this study, chimeric VLP were investigated displaying the 195 N-terminal amino acids derived from the glycoprotein E2 of the bovine viral diarrhea virus (BVDV) on their surface. Isolation of the VLP from methylotrophic yeast Hansenula polymorpha was allowed upon co-expression of wild-type dS and a fusion protein composed of the BVDV-derived antigen N-terminally fused to the dS. It was shown the VLP could be purified by a process adapted from the production of a recombinant hepatitis B VLP vaccine. However, the process essentially depended on costly ultracentrifugation which is critical for low cost production. In novel process variants, this step was avoided after modification of the initial batch capture step, the introduction of a precipitation step and adjusting the ion exchange chromatography. The product yield could be improved by almost factor 8 to 93 ± 12 mg VLP protein per 100 g dry cell weight while keeping similar product purity and antigenicity. This allows scalable and cost efficient VLP production.
Asunto(s)
Virus de la Diarrea Viral Bovina/inmunología , Pichia/metabolismo , Vacunas de Partículas Similares a Virus/aislamiento & purificación , Proteínas del Envoltorio Viral/metabolismo , Vacunas Virales/aislamiento & purificación , Secuencia de Aminoácidos , Proteínas de la Cápside/genética , Virus de la Diarrea Viral Bovina/genética , Pichia/genética , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Vacunas de Partículas Similares a Virus/metabolismo , Proteínas del Envoltorio Viral/química , Proteínas del Envoltorio Viral/genética , Vacunas Virales/metabolismoRESUMEN
Porcine reproductive and respiratory syndrome virus (PRRSV) still poses a threat to the swine industry worldwide. Currently, commercial vaccines against PRRSV, which consist of modified live or inactivated virus, reduce symptoms and viremia in immunized pigs, but efficacy against heterologous strains is variable. This has led to the development of subunit vaccines that contain viral antigens that show the highest variability. In this work, a chimeric protein comprising short amino acid sequences from glycoprotein 3 (GP3), glycoprotein 4 (GP4), glycoprotein 5 (GP5), and M (matrix protein) proteins of PRRSV was designed and expressed in Escherichia coli. This protein, designated as PRRSVchim, was purified by immobilized metal affinity chromatography and evaluated. PRRSVchim was identified by immunoglobulin G (IgG) presence in serum samples from PRRSV-positive pigs. Also, the protein probed to be antigenic in immunized mice and piglets and provided some degree of protection against challenge with a PRRSV field isolate. These results show the potential of PRRSVchim protein for both PRRSV diagnostic and immunoprophylaxis.